These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31562829)

  • 21. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA
    Marren SM; Hammersley S; McDonald TJ; Shields BM; Knight BA; Hill A; Bolt R; Tree TI; Roep BO; Hattersley AT; Jones AG; Oram RA;
    Diabet Med; 2019 Sep; 36(9):1092-1099. PubMed ID: 30955221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
    Osei K; Falko JM
    Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy.
    Shah B; Breidbart E; Pawelczak M; Lam L; Kessler M; Franklin B
    J Pediatr Endocrinol Metab; 2012; 25(3-4):353-6. PubMed ID: 22768668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
    Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.
    Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D
    Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes.
    Pearson ER; Liddell WG; Shepherd M; Corrall RJ; Hattersley AT
    Diabet Med; 2000 Jul; 17(7):543-5. PubMed ID: 10972586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
    Stanik J; Dankovcikova A; Barak L; Skopkova M; Palko M; Divinec J; Klimes I; Gasperikova D
    Diabet Med; 2018 Mar; 35(3):386-391. PubMed ID: 29278452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies.
    Hambling CE; Seidu SI; Davies MJ; Khunti K
    Diabet Med; 2017 Sep; 34(9):1219-1227. PubMed ID: 28498634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoglycemia in People with Type 2 Diabetes and CKD.
    Ahmad I; Zelnick LR; Batacchi Z; Robinson N; Dighe A; Manski-Nankervis JE; Furler J; O'Neal DN; Little R; Trence D; Hirsch IB; Bansal N; de Boer IH
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):844-853. PubMed ID: 30996047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.
    Weissman PN; Carr MC; Ye J; Cirkel DT; Stewart M; Perry C; Pratley R
    Diabetologia; 2014 Dec; 57(12):2475-84. PubMed ID: 25208756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.
    Riddle MC; Schneider J
    Diabetes Care; 1998 Jul; 21(7):1052-7. PubMed ID: 9653594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?
    Zenari L; Marangoni A
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():17-25. PubMed ID: 24034516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial.
    Ajjan RA; Jackson N; Thomson SA
    Diab Vasc Dis Res; 2019 Jul; 16(4):385-395. PubMed ID: 31271312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
    Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
    Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.